Mobocertinib added in NICE guidelines
NICE guidelines have added the guidance on mobocertinib to the systemic anti-cancer therapy treatment pathways for advanced non-small-cell lung cancer.
They would like your feedback on how the treatment pathways present content from different sources (NICE technology appraisal guidance, guideline recommendations, and expert input). To comment, go to the link below on systemic anti-cancer therapy for advanced non-small-cell lung cancer and fill in the pop-up survey.
Recent Posts
Novartis Acquires Mutant-Selective PI3Kα Inhibitor to Enhance Breast Cancer Treatment Options
Novartis has agreed to acquire SNV4818, a pan-mutant-selective PI3Kα inhibitor from Synnovation Therapeutics, targeting PIK3CA mutations...
Semaglutide India Partnership: Enhancing Access to Diabetes Treatment
The Semaglutide India partnership between Lupin Limited and Zydus Lifesciences Limited formalizes a licensing and supply agreement to co-market an innovative Semaglutide Injection (15 mg/3 ml) with a patient-friendly reusable pen device in the Indian market. This collaboration leverages Lupin's e...
Wegovy HD Approval: A Game Changer in Obesity Treatment and Weight Loss Efficacy
Novo Nordisk announced the Wegovy HD approval by the US Food and Drug Administration (FDA) for Wegovy® HD (semaglutide injection 7.2 mg), a higher-dose formulation showing superior weight loss over the existing 2.4 mg dose in adults with obesity. In the STEP UP trial, this new dose delivered an a...